Literature DB >> 9550282

Effect of oral and intravenous insulin and glutamic acid decarboxylase in NOD mice.

V K Ramiya1, X Z Shang, C H Wasserfall, N K Maclaren.   

Abstract

Islet cell antigens have been administered orally and intravenously (I.V.) to NOD mice to assess their abilities to protect from or delay the onset of diabetes, and thereby provide insights that may have therapeutic implications in human trials. Whereas we and others have observed a delay in the onset of diabetes in NOD mice that have been fed with insulin from early life, we report here for the first time that feedings with porcine GAD65 alone (p = 0.226) or in combination with insulin (p = 0.011), have anti-diabetic effects in a prolonged study period (>400 days). While antigen-specific inhibitions of in vitro lymphocytic proliferation responses were seen (p < 0.05), antibody levels were unaffected by oral antigen treatments. IFN-gamma mRNA levels were downregulated in the islet infiltrates following oral antigen treatments while IL-2 and TNF-beta were expressed in all instances. We also observed that I.V. human recombinant GAD65, and porcine GAD given at weaning, delayed diabetes onset (p = 0.004) while similar treatments with a variety of inactive insulin preparations were generally ineffective. These findings thus indicate varying effects of oral and I.V. autoantigen administrations on the development of diabetes in NOD mice, and describe the immunological processes induced by oral autoantigen treatments.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9550282     DOI: 10.3109/08916939708994736

Source DB:  PubMed          Journal:  Autoimmunity        ISSN: 0891-6934            Impact factor:   2.815


  11 in total

1.  Nasal administration of CTB-insulin induces active tolerance against autoimmune diabetes in non-obese diabetic (NOD) mice.

Authors:  C Aspord; C Thivolet
Journal:  Clin Exp Immunol       Date:  2002-11       Impact factor: 4.330

Review 2.  T-cell autoantigens in the non-obese diabetic mouse model of autoimmune diabetes.

Authors:  Jeffrey Babad; Ari Geliebter; Teresa P DiLorenzo
Journal:  Immunology       Date:  2010-10-13       Impact factor: 7.397

3.  Cytokine profile and insulin antibody IgG subclasses in patients with recent onset type 1 diabetes treated with oral insulin.

Authors:  L Monetini; M G Cavallo; E Sarugeri; F Sentinelli; L Stefanini; E Bosi; R Thorpe; P Pozzilli
Journal:  Diabetologia       Date:  2004-10-22       Impact factor: 10.122

4.  Inducing immune tolerance: a focus on Type 1 diabetes mellitus.

Authors:  Dan Xu; Suchitra Prasad; Stephen D Miller
Journal:  Diabetes Manag (Lond)       Date:  2013-09-01

Review 5.  Antigen-specific therapeutic approaches in Type 1 diabetes.

Authors:  Xavier Clemente-Casares; Sue Tsai; Carol Huang; Pere Santamaria
Journal:  Cold Spring Harb Perspect Med       Date:  2012-02       Impact factor: 6.915

6.  Immunotherapy for the prevention and treatment of type 1 diabetes: optimizing the path from bench to bedside.

Authors:  Damien Bresson; Matthias von Herrath
Journal:  Diabetes Care       Date:  2009-10       Impact factor: 17.152

7.  Oral Administration of Silkworm-Produced GAD65 and Insulin Bi-Autoantigens against Type 1 Diabetes.

Authors:  Baoping Liu; Yuan Yue; Yun Yang; Yongfeng Jin
Journal:  PLoS One       Date:  2016-01-19       Impact factor: 3.240

8.  Plant-based vaccines for oral delivery of type 1 diabetes-related autoantigens: Evaluating oral tolerance mechanisms and disease prevention in NOD mice.

Authors:  Amanda L Posgai; Clive H Wasserfall; Kwang-Chul Kwon; Henry Daniell; Desmond A Schatz; Mark A Atkinson
Journal:  Sci Rep       Date:  2017-02-13       Impact factor: 4.379

Review 9.  Immunotherapy of type 1 diabetes: lessons for other autoimmune diseases.

Authors:  Jean-François Bach
Journal:  Arthritis Res       Date:  2002-05-09

10.  Prevention or early cure of type 1 diabetes by intranasal administration of gliadin in NOD mice.

Authors:  David P Funda; Petra Fundova; Axel Kornerup Hansen; Karsten Buschard
Journal:  PLoS One       Date:  2014-04-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.